All In Biotech

Drug Trial Radar · NCT07854847

Study Interchangeability Hep-B Vaccine Administered at Birth Dose

Randomized, Double-Blind, Interchangeability Study of In-House Recombinant Hepatitis B (Bio Farma) at Birth Dose Followed by RRegistered DTwP-HepB-IPV-Hib (HEXASIIL) Vaccine in Indonesian Infants

Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 270 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

270

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Feb 2027

Study completion Jul 2027

Sponsor

Lead sponsor
PT Bio FarmaIndustry
Sponsor type
Industry
Collaborators
Universitas Padjadjaran
First posted
Oct 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 0 days, up to 3 days
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This trial is a randomized, double-blind, two arms parallel groups, prospective intervention study.

Conditions

  • Vaccination Adverse Event
  • Immunogenicity, Vaccine

Interventions

  • In-house Hepatitis B VaccineBiological

    0,5 ml In-House Recombinant Hepatitis B (Bio Farma) vaccine injected approximately at birth. The vaccines will be injected intramuscularly into the right anterolateral thigh

  • Registered Hepatitis B VaccineBiological

    0,5 ml Registered Recombinant Hepatitis B (Bio Farma) vaccine injected approximately at birth. The vaccines will be injected intramuscularly into the right anterolateral thigh

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Protectivity of primary series In-House Recombinant Hepatitis B vaccineTime frame: 28 days after administration of third dose of DTwP-HepB-IPV-Hib (HEXASIIL) vaccine

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.